Literature DB >> 16197341

The potential of antibody-mediated immunity in the defence against biological weapons.

Arturo Casadevall1, Liise-anne Pirofski.   

Abstract

Antibody-mediated immunity (AMI) has been used for the treatment and prevention of infectious diseases for > 100 years, and has a remarkable record of safety, efficacy and versatility. AMI can be used for defence against a wide variety of biological weapons, and passive antibody (Ab) therapy has the potential to provide immediate immunity to susceptible individuals. Recent advances in the Ab field make it possible to generate Abs with enhanced antimicrobial functions. There are significant gaps in our understanding of Ab function, such that the development of Ab-based strategies remains a largely empirical exercise. Nevertheless, the advantages inherent in the therapeutic and prophylactic use of AMI provide a powerful rationale for continued development that will undoubtedly yield many new vaccines and therapeutic Abs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16197341     DOI: 10.1517/14712598.5.10.1359

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  3 in total

1.  Antibody Preparations from Human Transchromosomic Cows Exhibit Prophylactic and Therapeutic Efficacy against Venezuelan Equine Encephalitis Virus.

Authors:  Christina L Gardner; Chengqun Sun; Thomas Luke; Kanakatte Raviprakash; Hua Wu; Jin-An Jiao; Eddie Sullivan; Douglas S Reed; Kate D Ryman; William B Klimstra
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

2.  Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant.

Authors:  Cassandra D Kelly; Chris O'Loughlin; Frank B Gelder; Johnny W Peterson; Laurie E Sower; Nick M Cirino
Journal:  J Immune Based Ther Vaccines       Date:  2007-10-22

Review 3.  Exploring the native human antibody repertoire to create antiviral therapeutics.

Authors:  S K Dessain; S P Adekar; J D Berry
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.